Lieftink, Cor

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

Sun, C., Wang, L., Huang, S., Heynen, G. J. J. E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S. M., et al. (2014) · Nature

Melanoma and MAPK PathwaysLung Cancer Treatments and Mutations

Cited by 888

Inducing and exploiting vulnerabilities for the treatment of liver cancer

Wang, C., Vegna, S., Jin, H., Benedict, B., Lieftink, C., Ramirez, C., de Oliveira, R. L., Morris, B., Gadiot, J., Wang, W., et al. (2019) · Nature

Telomeres, Telomerase, and SenescenceHepatocellular Carcinoma Treatment and Prognosis

Cited by 427

SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo

Mainardi, S., Mulero-Sánchez, A., Prahallad, A., Germano, G., Bosma, A., Krimpenfort, P., Lieftink, C., Steinberg, J. D., de Wit, N., Gonçalves-Ribeiro, S., et al. (2018) · Nature Medicine

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 320

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3

Sun, C., Hobor, S., Bertotti, A., Zecchin, D., Huang, S., Galimi, F., Cottino, F., Prahallad, A., Grernrum, W., Tzani, A., et al. (2014) · Cell Reports

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 304

High-Throughput Functional Genetic and Compound Screens Identify Targets for Senescence Induction in Cancer

Wang, L., Leite de Oliveira, R., Wang, C., Fernandes Neto, J. M., Mainardi, S., Evers, B., Lieftink, C., Morris, B., Jochems, F., Willemsen, L., et al. (2017) · Cell Reports

Telomeres, Telomerase, and SenescenceGenetics, Aging, and Longevity in Model Organisms

Cited by 224

PTPN11 is a central node in intrinsic and acquired resistance to targeted cancer drugs

Prahallad, A., Heynen, G. J. J. E., Germano, G., Willems, S. M., Evers, B., Vecchione, L., Gambino, V., Lieftink, C., Beijersbergen, R. L., Di Nicolantonio, F., et al. (2015) · Cell Reports

Protein Tyrosine PhosphatasesMelanoma and MAPK Pathways

Cited by 168

CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma

Wang, C., Wang, H., Lieftink, C., du Chatinier, A., Gao, D., Jin, G., Jin, H., Beijersbergen, R. L., Qin, W., & Bernards, R. (2020) · Gut

Hepatocellular Carcinoma Treatment and PrognosisCancer-related Molecular Pathways

Cited by 107

A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers

Šuštić, T., van Wageningen, S., Bosdriesz, E., Reid, R. J. D., Dittmar, J., Lieftink, C., Beijersbergen, R. L., Wessels, L. F. A., Rothstein, R., & Bernards, R. (2018) · Genome Medicine

Melanoma and MAPK PathwaysEndoplasmic Reticulum Stress and Disease

Cited by 42

Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity

Pogacar, Z., Johnson, J. L., Krenning, L., De Conti, G., Jochems, F., Lieftink, C., Velds, A., Wardak, L., Groot, K., Schepers, A., et al. (2022) · PLOS ONE

Telomeres, Telomerase, and SenescenceAdvanced Breast Cancer Therapies

Cited by 13

Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity

Pogacar, Z., Johnson, J. L., Krenning, L., De Conti, G., Lieftink, C., Velds, A., Wardak, L., Jochems, F., Groot, K., Schepers, A., et al. (2021) · PLoS ONE

Telomeres, Telomerase, and SenescenceAdvanced Breast Cancer Therapies

Cited by 13